Onderneming Nymox Pharmaceutical Corporation
Aandelen
NYMXF
BSP733981026
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,3 USD | 0,00% | +3,38% | -49,15% |
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paul Averback
CEO | Chief Executive Officer | 73 | 30-05-95 |
Patrick Doody
BRD | Director/Board Member | - | 12-07-23 |
Director/Board Member | - | 21-03-23 | |
Suresh Kalbag
PRN | Corporate Officer/Principal | - | - |
General Counsel | - | 06-02-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
David S. Morse
BRD | Director/Board Member | 67 | 08-06-06 |
Paul Averback
CEO | Chief Executive Officer | 73 | 30-05-95 |
Director/Board Member | 88 | 01-07-15 | |
Director/Board Member | - | 21-03-23 | |
Patrick Doody
BRD | Director/Board Member | - | 12-07-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 93 265 000 | 54 049 529 ( 57,95 %) | 0 | 57,95 % |
Bedrijfsgegevens
Sector
Verkoop per regio
Vaira. 1 jan. | Kapi. | |
---|---|---|
-49,15% | 28,01 mln. | |
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |
- Beurs
- Aandelen
- Koers NYMXF
- Onderneming Nymox Pharmaceutical Corporation